A 20-Week Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (ages 10-17) with Down syndrome

Principal Investigator: George Capone

The specific aims of this study are to: a) investigate short-term safety and efficacy of rivastigmine treatment; b) build upon the open-label treatment results of overall function and language improvement in children with Down syndrome (DS) in a double-blind, placebo-controlled clinical trial; and c) investigate other specific cognitive domains that may selectively respond to rivastigmine treatment.

Participate in Research:

If you or someone you know is interested in participating in this research study, please download this informational flyer.